A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis.

BACKGROUND: Linezolid is an effective, but toxic anti-tuberculosis drug that is currently recommended for the treatment of drug-resistant tuberculosis. Improved oxazolidinones should have a better safety profile, while preserving efficacy. Delpazolid is a novel oxazolidinone developed by LegoChem Biosciences Inc. that has been evaluated up to phase 2a clinical trials. Since oxazolidinone toxicity can occur late in treatment, LegoChem Biosciences Inc. and the PanACEA Consortium designed DECODE to be an innovative dose-ranging study with long-term follow-up for determining the exposure-response and exposure-toxicity relationship of delpazolid to support dose selection for later studies. Delpazolid is administered in combination with bedaquiline, delamanid and moxifloxacin. METHODS: Seventy-five participants with drug-sensitive, pulmonary tuberculosis will receive bedaquiline, delamanid and moxifloxacin, and will be randomized to delpazolid dosages of 0 mg, 400 mg, 800 mg, 1200 mg once daily, or 800 mg twice daily, for 16 weeks. The primary efficacy endpoint will be the rate of decline of bacterial load on treatment, measured by MGIT liquid culture time to detection from weekly sputum cultures. The primary safety endpoint will be the proportion of oxazolidinone class toxicities; neuropathy, myelosuppression, or tyramine pressor response. Participants who convert to negative liquid media culture by week 8 will stop treatment after the end of their 16-week course and will be observed for relapse until week 52. Participants who do not convert to negative culture will receive continuation phase treatment with rifampicin and isoniazid to complete a six-month treatment course. DISCUSSION: DECODE is an innovative dose-finding trial, designed to support exposure-response modelling for safe and effective dose selection. The trial design allows assessment of occurrence of late toxicities as observed with linezolid, which is necessary in clinical evaluation of novel oxazolidinones. The primary efficacy endpoint is the change in bacterial load, an endpoint conventionally used in shorter dose-finding trials. Long-term follow-up after shortened treatment is possible through a safety rule excluding slow-and non-responders from potentially poorly performing dosages. TRIAL REGISTRATION: DECODE was registered in ClinicalTrials.gov before recruitment start on 22 October 2021 (NCT04550832).

Xpert® MTB/RIF assay testing on stool for the diagnosis of paediatric pulmonary TB in Tanzania.

SETTING: Six health facilities in Dar es Salaam, Tanzania. OBJECTIVE: To evaluate the use of stool specimens in the diagnostic workup of paediatric TB using the Xpert® MTB/RIF assay. DESIGN: Between December 2018 and May 2019, we performed a cross-sectional diagnostic study of children aged between 1 month and 14 years with presumptive TB. A single stool specimen was tested using Xpert. The result was compared with the reference microbiological standard for respiratory or gastric specimens tested using Xpert and/or solid culture. The sensitivity, specificity and predictive values of stool Xpert assay were assessed. RESULTS: A total of 225 children with a median age of 2.17 years (IQR 1.16-5.19) were enrolled; 165/225 (73.3%) were aged <5 years. Of 225 children, 8 (3.6%) were diagnosed with TB as they were culture- or Xpert-positive on sputum/gastric aspirate. The stool Xpert assay showed a sensitivity of 62.5% (95% CI 25-92) and specificity of 100% (95% CI 98-100) against the reference standard. CONCLUSION: Use of the Xpert assay on stool specimens had a moderate sensitivity and high specificity in the diagnosis of pulmonary TB in children. Our data adds to the body of evidence for the use of Xpert assay on stool as a non-respiratory specimen to complement conventional methods used to diagnose the disease.

CONTEXTE: Six structures de santé à Dar es Salaam, Tanzanie. OBJECTIF: Evaluer l'utilisation d'échantillons de selles dans le bilan diagnostique de la TB pédiatrique en utilisant le test Xpert® MTB/RIF. SCHÉMA: Entre décembre 2018 et mai 2019, nous avons réalisé une étude transversale de bilans d'enfants âgés d'un mois à 14 ans avec la TB présumée. Un échantillon unique de selles a été testé par l'Xpert. Le résultat a été comparé avec comme référence le standard microbiologique d'échantillons respiratoires ou gastriques testés par test Xpert et/ou culture solide. La sensibilité, la spécificité et les valeurs prédictives de l'Xpert sur les selles ont été évaluées. RÉSULTATS: Ont été enrôlés 225 enfants d'âge médiane 2,17 ans (IQR 1,16­5,19) dont 165 (73,3%) avaient moins de cinq ans. Huit (3,6%) enfants ont eu un diagnostic de TB par culture ou test Xpert positif sur aspiration de crachats/gastrique. Le test Xpert sur les selles a montré une sensibilité de 62,5% (IQR 25­92) et une spécificité de 100% (IQR 98­100) vis-à-vis du standard de référence. CONCLUSION: Le recours au test Xpert sur des échantillons de selles a montré une sensibilité modérée et une spécificité élevée dans le diagnostic de la TB pulmonaire des enfants. Nous données confirment l'intérêt de l'utilisation du test Xpert sur les selles comme échantillon non respiratoire pour compléter les méthodes conventionnelles de diagnostic de la maladie.

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB.

BACKGROUND: Treatment for TB is lengthy and toxic, and new regimens are needed.METHODS: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin (M) and 1500 mg pyrazinamide (Z) for 6 months (6Pa200MZ) or 4 months (4Pa200MZ); 100 mg pretomanid daily for 4 months in the same combination (4Pa100MZ); or standard DS-TB treatment for 6 months. The primary outcome was treatment failure or relapse at 12 months post-randomisation. The non-inferiority margin for between-group differences was 12.0%. Recruitment was paused following three deaths and not resumed.RESULTS: Respectively 4/47 (8.5%), 11/57 (19.3%), 14/52 (26.9%) and 1/53 (1.9%) DS-TB outcomes were unfavourable in patients on 6Pa200MZ, 4Pa200MZ, 4Pa100MZ and controls. There was a 6.6% (95% CI -2.2% to 15.4%) difference per protocol and 9.9% (95%CI -4.1% to 23.9%) modified intention-to-treat difference in unfavourable responses between the control and 6Pa200MZ arms. Grade 3+ adverse events affected 68/203 (33.5%) receiving experimental regimens, and 19/68 (27.9%) on control. Ten of 203 (4.9%) participants on experimental arms and 2/68 (2.9%) controls died.CONCLUSION: PaMZ regimens did not achieve non-inferiority in this under-powered trial. An ongoing evaluation of PMD remains a priority.

Prevalence and clinical significance of respiratory viruses and bacteria detected in tuberculosis patients compared to household contact controls in Tanzania: a cohort study.

OBJECTIVES: To describe the prevalence of respiratory pathogens in tuberculosis (TB) patients and in their household contact controls, and to determine the clinical significance of respiratory pathogens in TB patients. METHODS: We studied 489 smear-positive adult TB patients and 305 household contact controls without TB with nasopharyngeal swab samples within an ongoing prospective cohort study in Dar es Salaam, Tanzania, between 2013 and 2015. We used multiplex real-time PCR to detect 16 respiratory viruses and seven bacterial pathogens from nasopharyngeal swabs. RESULTS: The median age of the study participants was 33 years; 61% (484/794) were men, and 21% (168/794) were HIV-positive. TB patients had a higher prevalence of HIV (28.6%; 140/489) than controls (9.2%; 28/305). Overall prevalence of respiratory viral pathogens was 20.4% (160/794; 95%CI 17.7-23.3%) and of bacterial pathogens 38.2% (303/794; 95%CI 34.9-41.6%). TB patients and controls did not differ in the prevalence of respiratory viruses (Odds Ratio [OR] 1.00, 95%CI 0.71-1.44), but respiratory bacteria were less frequently detected in TB patients (OR 0.70, 95%CI 0.53-0.94). TB patients with both respiratory viruses and respiratory bacteria were likely to have more severe disease (adjusted OR [aOR] 1.6, 95%CI 1.1-2.4; p 0.011). TB patients with respiratory viruses tended to have more frequent lung cavitations (aOR 1.6, 95%CI 0.93-2.7; p 0.089). CONCLUSIONS: Respiratory viruses are common for both TB patients and household controls. TB patients may present with more severe TB disease, particularly when they are co-infected with both bacteria and viruses.

Screening for pulmonary tuberculosis in a Tanzanian prison and computer-aided interpretation of chest X-rays.

SETTING: Tanzania is a high-burden country for tuberculosis (TB), and prisoners are a high-risk group that should be screened actively, as recommended by the World Health Organization. Screening algorithms, starting with chest X-rays (CXRs), can detect asymptomatic cases, but depend on experienced readers, who are scarce in the penitentiary setting. Recent studies with patients seeking health care for TB-related symptoms showed good diagnostic performance of the computer software CAD4TB. OBJECTIVE: To assess the potential of computer-assisted screening using CAD4TB in a predominantly asymptomatic prison population. DESIGN: Cross-sectional study. RESULTS: CAD4TB and seven health care professionals reading CXRs in local tuberculosis wards evaluated a set of 511 CXRs from the Ukonga prison in Dar es Salaam. Performance was compared using a radiological reference. Two readers performed significantly better than CAD4TB, three were comparable, and two performed significantly worse (area under the curve 0.75 in receiver operating characteristics analysis). On a superset of 1321 CXRs, CAD4TB successfully interpreted >99%, with a predictably short time to detection, while 160 (12.2%) reports were delayed by over 24 h with conventional CXR reading. CONCLUSION: CAD4TB reliably evaluates CXRs from a mostly asymptomatic prison population, with a diagnostic performance inferior to that of expert readers but comparable to local readers.

Contexte : La Tanzanie est lourdement frappée par la tuberculose (TB) et les prisonniers sont un groupe à haut risque qui devrait bénéficier d'un dépistage actif, comme le recommande l'Organisation Mondiale de la Santé. Les algorithmes de dépistage qui débutent par une radiographie pulmonaire peuvent détecter des cas asymptomatiques, mais ils requièrent des lecteurs de radiographies expérimentés, qui sont rares dans le contexte pénitentiaire. Des études récentes sur des patients sollicitant des soins pour des symptômes liés à la TB ont mis en évidence une bonne performance diagnostique du logiciel CAD4TB.Objectif : Evaluer le potentiel d'un dépistage assisté par ordinateur en utilisant CAD4TB au sein d'une population carcérale en majorité asymptomatique.Schéma : Étude transversale.Résultats : CAD4TB et sept professionnels de santé lisant des radiographies dans des services de TB locaux ont évalué un ensemble de 511 radiographies pulmonaires provenant de la prison d'Ukonga à Dar es Salaam et les performances ont été comparées grâce à une radiographie de référence. Deux lecteurs ont été significativement plus performants que CAD4TB, trois ont été comparables et deux ont été significativement moins bons (zone sous la courbe de 0,75 dans l'analyse ROC ­fonction d'efficacité du receveur). Sur un ensemble de 1321 radiographies pulmonaires, CAD4TB en a interprété avec succès plus de 99% avec un délai de détection prévisible court, tandis que 160 (12,2%) réponses ont été retardées de plus de 24 h avec la méthode de lecture conventionnelle.Conclusion : CAD4TB évalue de manière fiable les radiographies pulmonaires dans une population en majorité asymptomatique de détenus, avec une performance diagnostique inférieure à celle de lecteurs experts mais comparable à celle des lecteurs locaux.

Marco de referencia: Tanzania es un país con una alta tasa de morbilidad por tuberculosis (TB) y las personas en los establecimientos penitenciarios constituyen un grupo de alto riesgo de contraer la enfermedad; en esta población se debe practicar la detección sistemática activa como lo recomienda la Organización Mundial de la Salud. Los algoritmos de detección cuya etapa inicial es la radiografía de tórax pueden detectar los casos asintomáticos, pero su eficacia depende de la experiencia del profesional que interpreta las imágenes y esta competencia es escasa en los entornos penitenciarios. Algunos estudios recientes de pacientes que buscan atención sanitaria por síntomas asociados con la TB han revelado un buen rendimiento diagnóstico con la utilización del programa informático CAD4TB. Objetivo: Evaluar la utilidad de la detección sistemática de la TB asistida por el programa CAD4TB, en una población penitenciaria en su mayoría asintomática.Método: Fue este un estudio de tipo transversal.Resultados: Siete profesionales de atención sanitaria de los servicios locales de TB analizaron 511 radiografías de tórax provenientes de la prisión de Ukonga, en Dar es-Salam, con la ayuda del programa CAD4TB; se preparó un conjunto de referencia radiográfica de lectura con el fin de evaluar el rendimiento diagnóstico. El desempeño de dos de los lectores fue significativamente superior al resultado del programa CAD4TB, tres lectores obtuvieron una puntuación comparable al programa y en dos lectores se observó un rendimiento significativamente inferior (área bajo la curva: 0,75 en el análisis de eficacia diagnóstica). En un conjunto especial de 1321 radiografías de tórax el programa CAD4TB interpretó eficazmente más del 99%, con un corto lapso previsible hasta la detección, en contraste con la lectura clásica de las radiografías que dio lugar a un retraso superior a 24 horas en 160 informes (12,2%).Conclusión: El programa CAD4TB realizó una evaluación fiable de las radiografías provenientes de una población penitenciaria en su mayor parte asintomática. El rendimiento diagnóstico del programa fue inferior al rendimiento de los lectores expertos, pero comparable con el rendimiento de los lectores locales.